Skip to main content

The RheumNow Week in Review – 9 June 2017

Jun 09, 2017 3:00 am

Dr. Jack Cush reviews the news and reports of interest from RheumNow in the last week:

  1. Abbvie Scholarship program accepting applications to award 15 grants ($15k/yr) to Students with Rheumatic disorders https://t.co/lgDLQRznJN
  2. Using Claims data, Allopurinol associated with lower risk of incident renal disease (HR 0.61) compared to febuxostat https://t.co/iGUKB4MxK0
  3. SLE myositis more likely to have rash, alopecia, pericarditis, vasculitis, Sm, RNP, dsDNA, low Plts & WBC, low C3.C4 https://t.co/UwWVr1XuhY
  4. Autoimmune diseases w/ MYOCARDITIS include sarcoidosis, Behçets, Churg-Strauss, inflammatory myositis, SLE https://t.co/zb3LdzUL9G
  5. QUEST-RA study shows the average RA pt has 2+ comorbidities (HTN, OP,OA); fatigue assoc w/ comorbidity & dz activity https://t.co/BPTsGW82ho
  6. Retro review of open label Tofacitinib 5 mg bid in 13 pts w/ alopecia areata showing ~50% regrowth after 4-5 mos https://t.co/Umw6vCOp3j
  7. Case reports showing tofacitinib, ruloxocitinb efficacy in difficult dermatomyositis, leads makers of JAK inhibitors to consider RCTs in DM
  8. Metormins effx mediated by change in gut microbiome; transfer of metformin-altered microbiota improves Glu tolerance https://t.co/1HvCnS19kW
  9. FDA Requests Removal of OPANA-ER from the Market 
  10. Debate over Alcohol and Methotrexate Precautions 
  11. Biosimilar Reports – May 2017
  12. Higher Fracture Risks with Prolonged Bisphosphonate Use in Older Women

 

 

 

Disclosures
The author has received compensation as an advisor or consultant on this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×